Simplex Trading
DYN icon

Simplex Trading’s Dyne Therapeutics DYN Stock Holding History

Simplex Trading’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144K Buy
6,500
+600
+10% +$11.2K ﹤0.01% 5125
2026
Q1 		$107K Sell
5,900
-3,000
-34% -$51.7K ﹤0.01% 5003
2025
Q4 		$174K Sell
8,900
-1,400
-14% -$26.5K ﹤0.01% 4367
2025
Q3 		$130K Sell
10,300
-900
-8% -$10.3K ﹤0.01% 5452
2025
Q2 		$106K Buy
+11,200
New +$123K ﹤0.01% 5175
2025
Q1 		– Sell
-900
Closed -$21K – 8742
2024
Q4 		$21K Buy
900
+500
+125% +$14.8K ﹤0.01% 6639
2024
Q3 		$14K Sell
400
-2,400
-86% -$95.5K ﹤0.01% 6938
2024
Q2 		$98K Sell
2,800
-119,300
-98% -$3.47M ﹤0.01% 5398
2024
Q1 		$3.47M Buy
122,100
+118,700
+3,491% +$2.68M ﹤0.01% 1908
2023
Q4 		$45K Buy
+3,400
New +$33.2K ﹤0.01% 6170
2022
Q4 		– Sell
-800
Closed -$10K – 9438
2022
Q3 		$10K Buy
+800
New +$9.17K ﹤0.01% 8229
2022
Q2 		– Sell
-200
Closed -$1K – 10172
2022
Q1 		$1K Buy
+200
New +$1.7K ﹤0.01% 10052

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Simplex Trading's DYN Position: Q2 2026 in Review

Simplex Trading increased its Dyne Therapeutics (DYN) stake by 16% in Q2 2026, buying an estimated $5.08K and bringing the position to 2,007 shares worth $44.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6410.

Simplex Trading first reported a position in DYN in Q2 2022 and has held it in 11 quarters since. The position peaked at $1.41M in Q1 2024. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Simplex Trading held 2,007 shares of Dyne Therapeutics worth $44.6K as of Q2 2026.
  • Simplex Trading bought 273 Dyne Therapeutics shares in Q2 2026, an estimated $5.08K.
  • Dyne Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #6410 holding.
  • Simplex Trading first reported a position in Dyne Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • Simplex Trading's Dyne Therapeutics position peaked at $1.41M in Q1 2024.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.